LIPO · Lipella Pharmaceuticals Inc. · Debt
$0.00
At close · Nov 11
Return incl. dividend (before tax)
Going-concern doubt
— flagged Nov 14, 2025
Substantial doubt about the company's ability to continue as a going concern.
“These factors individually and collectively raise substantial doubt about the Company's ability to continue as a going concern. The accompanying unaudited condensed financial statements do not include any adjustments that may result from this uncertainty.”View the 10-Q filed Nov 14, 2025
Market Cap
$2,773
Shares
4.62M
Volume · Nov 11
43.34K
Avg daily vol (3M)
3997
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Read debt and covenant terms in your AI or your code through MCP and the API →Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current operating lease liabilities | 2025-09-30 | USD 44,267 | 10-Q filed 2025-11-14 |
| Noncurrent operating lease liabilities | 2025-09-30 | USD 219,816 | 10-Q filed 2025-11-14 |
| Notes payable, including current maturities | 2025-09-30 | USD 0 | 10-Q filed 2025-11-14 |
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.